Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Hydrochlorothiazide Effects on BP and Sympathetic Nerve Activity in T2DM
NCT03254849Phase 4Completed
- Sponsor
- Profil
- Start
- Dec 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (2 arms), sponsored by Profil. Primary endpoint: Blood Pressure reduction at 6 weeks. Started Dec 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT03254849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254849.